(120 days)
Not Found
No
The summary does not mention AI, ML, or any related terms, and the device description focuses on a disposable pump for insulin delivery.
Yes
The device is indicated for the continuous delivery of insulin for the management of diabetes mellitus, which is a therapeutic purpose.
No
The device is described as an "insulin delivery system" and a "disposable pump for the basal and bolus delivery of insulin." Its function is to deliver insulin, not to diagnose a condition.
No
The device description explicitly states it is a "disposable pump," which is a hardware component for insulin delivery.
No, based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "for the continuous delivery of insulin... for the management of diabetes mellitus in persons requiring insulin." This describes a device that delivers a substance into the body for therapeutic purposes.
- Device Description: The device is described as a "disposable pump for the basal and bolus delivery of insulin." This further reinforces its function as a drug delivery system.
- Lack of IVD Characteristics: IVD devices are used to examine specimens (like blood, urine, or tissue) outside the body to provide information for diagnosis, monitoring, or screening. The provided information does not mention any such function.
Therefore, the BioValve Insulin Delivery System (BIDS) is a therapeutic device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The BioValve Insulin Delivery System (BIDS) is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin.
Product codes
LZG, FPA
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The information provided supports that the performance of the pumps is equivalent to the predicate devices.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5725 Infusion pump.
(a)
Identification. An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner. The device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically. The device may also operate using a constant force to propel the fluid through a narrow tube which determines the flow rate. The device may include means to detect a fault condition, such as air in, or blockage of, the infusion line and to activate an alarm.(b)
Classification. Class II (performance standards).
0
510(K) SUMMARY
9.0 Summary of Safety and Effectiveness
| 9.1 Submitted By: | Scott Huie |
|---|---|
| Vice President of Operations | |
| Biovalve Technologies, Inc | |
| Date Prepared: | April 15, 2005 |
| 9.2 Trade/Proprietary Name: BioValve Insulin Delivery Systems (BIDS) | |
| 9.3 Common/Usual Name: | Disposable Insulin Infusion Pump |
| 9.4 Classification Name: | Pump, Infusion, Insulin/Set, Administration, Intravascular |
| 9.5 Classification: FDA has classified Infusion Pumps and Intravascular Catheters in | |
| Class II. Final Order was published in the Federal Register on October 21, 1980 after | |
| review by the General Hospital and Personal Use Devices Classification Panel. | |
| Panel: 80 Procodes: | LZG External Insulin Infusion Pump |
| FPA Intravascular Administration Set | |
| 9.6 Purpose of Submission | |
| BioValve Technologies proposes to market a disposable pump for the basal and bolus | |
| delivery of insulin. |
9.7 Substantial Equivalence
The BioValve Insulin Delivery Systems (BIDS) is substantially equivalent to the Insulet iXL Diabetes Management System (K031373) as well as other Insulin Infusion Pumps and Subcutaneous Insulin Infusion Sets.
9.8 Technological Characteristics
The technological characteristics for these devices differ from the predicate devices in as much as this device does not use electronic power or components nor is it software controlled.
9.9 Performance Data
The information provided supports that the performance of the pumps is equivalent to the predicate devices.
9.10 Conclusion
Biovalve, Inc. concludes based on the information presented that the modified product is substantially equivalent to the current product legally marketed in the USA.
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health and Human Services (HHS). The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or feathers. The bird is positioned within a circular border, and the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA" is arranged around the circumference of the circle.
AUG 1 6 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Scott Huie Vice President of Operations BioValve Technologies, Incorporated 155 Flanders Rd. Westborough, Massachusetts 01581
Re: K050971
Trade/Device Name: BioValve Insulin Delivery Systems (BIDS) Regulation Number: 21 CFR 880.5725 Regulation Name: Insulin Infusion Pump Regulatory Class: II Product Code: LZG Dated: June 30, 2005 Received: July 1, 2005
Dear Mr. Huie:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
2
Page 2 - Mr. Huie
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Chiu Lin, Ph.D. Director Director Division of Anesthesiology, General Hospital Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known): K050971
Device Name:
BioValve Insulin Delivery Systems (BIDS)
Indications For Use:
The BioValve Insulin Delivery System (BIDS) is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Chr
(Division Sign-Off) Division of Anesthesiology, General Hospital, Infection Control, Dental Devices
Page 1 of
510(k) Number: